222 related articles for article (PubMed ID: 33288156)
21. Pancreatic Neuroendocrine Tumors.
Salaria SN; Shi C
Surg Pathol Clin; 2016 Dec; 9(4):595-617. PubMed ID: 27926362
[TBL] [Abstract][Full Text] [Related]
22. Serotonin immunoreactive pancreatic neuroendocrine neoplasm associated with main pancreatic duct dilation: a recognizable entity with excellent long-term outcome.
Dioguardi Burgio M; Cros J; Panvini N; Depoilly T; Couvelard A; Ruszniewski P; de Mestier L; Hentic O; Sauvanet A; Dokmak S; Faccinetto A; Ronot M; Vilgrain V
Eur Radiol; 2021 Nov; 31(11):8671-8681. PubMed ID: 33977308
[TBL] [Abstract][Full Text] [Related]
23. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms.
Basturk O; Yang Z; Tang LH; Hruban RH; Adsay V; McCall CM; Krasinskas AM; Jang KT; Frankel WL; Balci S; Sigel C; Klimstra DS
Am J Surg Pathol; 2015 May; 39(5):683-90. PubMed ID: 25723112
[TBL] [Abstract][Full Text] [Related]
24. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap.
Umetsu SE; Kakar S; Basturk O; Kim GE; Chatterjee D; Wen KW; Hale G; Shafizadeh N; Cho SJ; Whitman J; Gill RM; Jones KD; Navale P; Bergsland E; Klimstra D; Joseph NM
Mod Pathol; 2023 Mar; 36(3):100065. PubMed ID: 36788102
[TBL] [Abstract][Full Text] [Related]
25. A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas.
Tang LH; Basturk O; Sue JJ; Klimstra DS
Am J Surg Pathol; 2016 Sep; 40(9):1192-202. PubMed ID: 27259015
[TBL] [Abstract][Full Text] [Related]
26. A Clinicopathologic and Molecular Update of Pancreatic Neuroendocrine Neoplasms With a Focus on the New World Health Organization Classification.
Fang JM; Shi J
Arch Pathol Lab Med; 2019 Nov; 143(11):1317-1326. PubMed ID: 31509453
[TBL] [Abstract][Full Text] [Related]
27. Utility of contrast-enhanced harmonic endoscopic ultrasonography for predicting the prognosis of pancreatic neuroendocrine neoplasms.
Ishikawa R; Kamata K; Hara A; Tanaka H; Okamoto A; Yamazaki T; Nakai A; Omoto S; Minaga K; Yamao K; Takenaka M; Minami Y; Watanabe T; Chiba Y; Chikugo T; Matsumoto I; Takeyama Y; Matsukubo Y; Hyodo T; Kudo M
Dig Endosc; 2021 Jul; 33(5):829-839. PubMed ID: 33020955
[TBL] [Abstract][Full Text] [Related]
28. Pancreatic neuroendocrine neoplasms: current state and ongoing controversies on terminology, classification and prognostication.
Taskin OC; Clarke CN; Erkan M; Tsai S; Evans DB; Adsay V
J Gastrointest Oncol; 2020 Jun; 11(3):548-558. PubMed ID: 32655934
[TBL] [Abstract][Full Text] [Related]
29. Pancreatic acinar cell carcinomas and mixed acinar-neuroendocrine carcinomas are more clinically aggressive than grade 1 pancreatic neuroendocrine tumours.
Kim JY; Brosnan-Cashman JA; Kim J; An S; Lee KB; Kim H; Park DY; Jang KT; Oh YH; Hruban RH; Heaphy CM; Hong SM
Pathology; 2020 Apr; 52(3):336-347. PubMed ID: 32111396
[TBL] [Abstract][Full Text] [Related]
30. Medical Treatment of Advanced Pancreatic Neuroendocrine Neoplasms.
Palmieri LJ; Dermine S; Barré A; Dhooge M; Brezault C; Cottereau AS; Coriat R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32549203
[TBL] [Abstract][Full Text] [Related]
31. Inverse expression of somatostatin and CXCR4 chemokine receptors in gastroenteropancreatic neuroendocrine neoplasms of different malignancy.
Kaemmerer D; Träger T; Hoffmeister M; Sipos B; Hommann M; Sänger J; Schulz S; Lupp A
Oncotarget; 2015 Sep; 6(29):27566-79. PubMed ID: 26259237
[TBL] [Abstract][Full Text] [Related]
32. Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms.
Andreasi V; Muffatti F; Guarneri G; Falconi M; Partelli S
Curr Treat Options Oncol; 2020 Apr; 21(6):48. PubMed ID: 32350693
[TBL] [Abstract][Full Text] [Related]
33. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification.
Ishida H; Lam AK
Crit Rev Oncol Hematol; 2020 Jan; 145():102835. PubMed ID: 31864179
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms.
Grolmusz VK; Kövesdi A; Borks K; Igaz P; Patócs A
Eur J Endocrinol; 2018 Oct; 179(4):219-228. PubMed ID: 30299890
[TBL] [Abstract][Full Text] [Related]
35. Somatostatin and chemokine CXCR4 receptor expression in pancreatic adenocarcinoma relative to pancreatic neuroendocrine tumours.
Kajtazi Y; Kaemmerer D; Sänger J; Schulz S; Lupp A
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2481-2493. PubMed ID: 31451931
[TBL] [Abstract][Full Text] [Related]
36. Classification of primary hepatic tumours in the dog.
van Sprundel RG; van den Ingh TS; Guscetti F; Kershaw O; Kanemoto H; van Gils HM; Rothuizen J; Roskams T; Spee B
Vet J; 2013 Sep; 197(3):596-606. PubMed ID: 24011584
[TBL] [Abstract][Full Text] [Related]
37. Platinum-Based Treatment for Well- and Poorly Differentiated Pancreatic Neuroendocrine Neoplasms.
Pulvirenti A; Raj N; Cingarlini S; Pea A; Tang LH; Luchini C; Chou JF; Grego E; Marinova I; Capanu M; Landoni L; Scarpa A; Allen PJ; Klimstra DS; Reidy-Lagunes DL
Pancreas; 2021 Feb; 50(2):138-146. PubMed ID: 33565789
[TBL] [Abstract][Full Text] [Related]
38. P53, KI-67, CD117 expression in gastrointestinal and pancreatic neuroendocrine tumours and evaluation of their correlation with clinicopathological and prognostic parameters.
Kımıloğlu Şahan E; Erdoğan N; Ulusoy İ; Samet E; Akyıldız İğdem A; Gönüllü D
Turk J Gastroenterol; 2015 Mar; 26(2):104-11. PubMed ID: 25835106
[TBL] [Abstract][Full Text] [Related]
39. Pancreatic neuroendocrine tumors: accurate grading with Ki-67 index on fine-needle aspiration specimens using the WHO 2010/ENETS criteria.
Farrell JM; Pang JC; Kim GE; Tabatabai ZL
Cancer Cytopathol; 2014 Oct; 122(10):770-8. PubMed ID: 25044931
[TBL] [Abstract][Full Text] [Related]
40. Immunohistochemical and in situ hybridization analyses of glucose transporter 2 in pancreatic neuroendocrine tumors: Possible glucose transporter 2 association with neoplastic insulin production.
Watanabe H; Fujishima F; Unno M; Sasano H; Suzuki T
Pathol Res Pract; 2024 Jan; 253():154966. PubMed ID: 38043192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
